Osteoarthritis of the hip

New England Journal of Medicine

Volumn 357, Issue 14, 2007, Pages 1413-1421

  Lane, Nancy E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIHISTAMINIC AGENT; CELECOXIB; CHONDROITIN SULFATE; CODEINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DIACETYLRHEIN; GLUCOSAMINE; HYALURONIC ACID; HYDROCODONE; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROTON PUMP INHIBITOR; SALICYLIC ACID; TRAMADOL;

ACUPUNCTURE; AGED; ANAMNESIS; ARTICLE; CARDIOVASCULAR SYMPTOM; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG MECHANISM; EDEMA; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HIP OSTEOARTHRITIS; HUMAN; INSOMNIA; KIDNEY FAILURE; KINESIOTHERAPY; KNEE OSTEOARTHRITIS; LABORATORY TEST; LIFESTYLE; MALE; MONOTHERAPY; MUSCLE WEAKNESS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOTOMY; PEPTIC ULCER; PERIPHERAL EDEMA; PHYSICAL EXAMINATION; PHYSIOTHERAPY; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; SEDATION; SIDE EFFECT; TOTAL HIP PROSTHESIS; DIFFERENTIAL DIAGNOSIS; HIP ARTHROPLASTY; PRACTICE GUIDELINE; REVIEW; RISK FACTOR;

AGED; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHROPLASTY, REPLACEMENT, HIP; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; OSTEOARTHRITIS, HIP; PHYSICAL THERAPY MODALITIES; PRACTICE GUIDELINES; RISK FACTORS;

EID: 34948849235     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp071112     Document Type: Article

References (57)

1. Felson D. Epidemiology of osteoarthritis. In: Brandt KD, Doherty M, Lohmander LS, eds. Osteoarthritis. Oxford, England: Oxford University Press, 2003:9-16.
2. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
3. Nevitt MC, Xu L, Zhang Y, et al. Very low prevalence of hip osteoarthritis among Chinese elderly in Beijing, China, compared with whites in the United States: the Beijing Osteoarthritis Study. Arthritis Rheum 2002;46:1773-9.
4. DiCesare PE, Abramson SB. Pathogenesis of osteoarthritis. In: Harris ED, Budd RC, Firestein GS, et al., eds. Kelley's textbook of rheumatology. 7th ed. Vol. 2. Philadelphia: Elsevier/Saunders, 2005:1493-513.
5. Lievense AM, Bierma-Zeinstra SA, Verhagen AP, Verhaar JAS, Koes BW. Influence of work on the development of osteoarthritis of the hip: a systematic review. J Rheumatol 2001;28:2520-8.
6. Lievense AM, Bierma-Zeinstra SA, Verhagen AP, Bernsen RM, Verhaar JAS, Koes BW. Influence of sporting activities on the development of osteoarthritis of the hip: a systematic review. Arthritis Rheum 2003;49:228-36.
7. Lievense AM, Bierma-Zeinstra SA, Verhagen AP, Verhaar JAS, Koes BW. Influence of hip dysplasia on the development of osteoarthritis of the hip. Ann Rheum Dis 2004;63:621-6.
8. Lane NE, Gore LR, Cummings SR, et al. Serum vitamin D levels and incident changes of radiographic hip osteoarthritis: a longitudinal study. Arthritis Rheum 1999;42:854-60.
9. Lane NE, Lin P, Christiansen L, et al. Association of mild acetabular dysplasia with an increased risk of incident hip osteoarthritis in elderly white women: the Study of Osteoporotic Fractures. Arthritis Rheum 2000;43:400-4.
10. Nevitt MC. Risk factors for knee, hip and hand osteoarthritis. In: Arden N, Cooper C, eds. Osteoarthritis handbook. London: Taylor & Francis, 2006:23-48.
11. Lane NE, Lian K, Nevitt MC, et al. Frizzled-related protein variants are risk factors for hip osteoarthritis. Arthritis Rheum 2006;54:1246-54.
12. Loughlin J. The genetic epidemiology of human primary osteoarthritis: current status. Expert Rev Mol Med 2005;7:1-12.
13. Lian K, Zmuda JM, Nevitt MC, et al. Type I collagen alpha1 Sp1 transcription factor binding site polymorphism is associated with reduced risk of hip osteoarthritis defined by severe joint space narrowing in elderly women. Arthritis Rheum 2005;52:1431-6.
14. Lian K, Lui L, Zmuda JM, et al. Estrogen receptor alpha genotype is associated with a reduced prevalence of radiographic hip osteoarthritis in elderly Caucasian women. Osteoarthritis Cartilage (in press).
15. Altman R, Alarćon G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991;34:505-14.
16. Dougados M. Clinical features of osteoarthritis. In: Harris ED, Budd RC, Firestein GS, et al., eds. Kelley's textbook of rheumatology. 7th ed. Vol. 2. Philadelphia: Elsevier/Saunders, 2005:1514-27.
17. Anderson BC. Evaluation of the adult with hip pain. Online no. 15.7. UpToDate, 2007. (Accessed September 7, 2007, at http://www.UpToDate.com.)
18. Steinberg GG, Seybold EA. Hip and pelvis. In: Steinberg GG, Akins CM, Baran DT, eds. Orthopaedics in primary care. 3rd ed. Baltimore: Lippincott Williams & Wilkins, 1999.
19. McConnell S, Kolopack P, Davis AM. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): review of its utility and measurement properties. Arthritis Rheum 2001;45:453-61.
20. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:669-81.
21. Lane NE, Nevitt MC, Genant HK, Hochberg MC. Reliability of new indices of radiographic osteoarthritis of the hand and hip and lumbar disc degeneration. J Rheumatol 1993;20:1911-8.
22. Osborne RH, Wilson T, Lorig KR, McColl GJ. Does self-management lead to sustainable health benefits in people with arthritis? A 2-year transition study of 452 Australians. J Rheumatol 2007;34:1112-7.
23. Warsi A, LaValley MP, Wang PS, Avorn J, Solomon DH. Arthritis self-management education programs: a meta-analysis of the effect on pain and disability. Arthritis Rheum 2003;48:2207-13.
24. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. I. Osteoarthritis of the hip. Arthritis Rheum 1995;38:1535-40.
25. Fransen M, McConnell S, Bell M. Therapeutic exercise for people with osteoarthritis of the hip or knee: a systematic review. J Rheumatol 2002;29:1737-45.
26. Hinman RS, Heywood SE, Day AR. Aquatic physical therapy for hip and knee osteoarthritis: results of a single-blinded randomized controlled trial. Phys Ther 2007;87:32-43.
27. Lievense AM, Bierma-Zeinstra SM, Verhagen PA, van Baar ME, Verhaar JS, Koes BW. Influence of obesity on the development of osteoarthritis of the hip: a systematic review. Rheumatology (Oxford) 2002;41:1155-62.
28. Witt CM, Jena S, Brinkhaus B, Liecker B, Wegscheider K, Willich SN. Acupuncture in patients with osteoarthritis of the knee or hip: a randomized, controlled trial with an additional nonrandomized arm. Arthritis Rheum 2006;54:3485-93.
29. Altman RD, Zinsenheim JR, Temple AR, Schweinle JE. Three-month efficacy and safety of acetominophen extended release for osteoarthritis pain of the hip or knee: a randomized, double-blind, placebo-controlled trial. Osteoarthritis Cartilage 2007;15:454-61.
30. Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006;1:CD004257.
31. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by nonsteroidal anti-inflammatory drugs: systematic review. BMJ 2004;329:948.
32. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002;325:619.
33. Jones DL, Westby MD, Greidanus N, et al. Update on hip and knee arthroplasty: current state of evidence. Arthritis Rheum 2005;53:772-80.
34. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000;43:1905-15.
35. The use of opioids for the treatment of chronic pain: a consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain 1997;13:6-8.
36. Felson DT. Osteoarthritis of the knee. N Engl J Med 2006;354:841-8. [Erratum, N Engl J Med 2006;354:2520.]
37. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 2003;163:169-78.
38. Lanas A, García-Rodríguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007;102:507-15.
39. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102. [Erratum, N Engl J Med 2006; 355:221.]
40. Peloso PM, Bellamy N, Bensen W, et al. Double-blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. J Rheumatol 2000;27:764-71.
41. Cepeda MS, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis: a systematic review and metaanalysis. J Rheumatol 2007;34:543-55.
42. Fernández-López JC, Ruano-Ravina A. Efficacy and safety of intraarticular hyaluronic acid in the treatment of hip osteoarthritis: a systematic review. Osteoarthritis Cartilage 2006;14:1306-11.
43. Qvistgaard E, Christensen R, Torp-Pedersen S, Bliddal H. Intra-articular treatment of hip osteoarthritis: a randomized trial of hyaluronic acid, corticosteroid, and isotonic saline. Osteoarthritis Cartilage 2006;14:163-70.
44. Plant MJ, Borg AA, Dziedzic K, Saklatvala J, Dawes PT. Radiographic patterns and response to corticosteroid hip injection. Ann Rheum Dis 1997;56:476-80.
45. Waseem M, Sadiq S, Gambhir AK, Lim J, Maxwell S, Bamford DJ. Safety and efficacy of intra-articular injection of the hip. Hip Int 2002;12:378-82.
46. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000;283:1469-75.
47. Leeb BF, Schweitzer H, Montag K, Smolen JS. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000;27:205-11.
48. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354:795-808.
49. Nguyen M, Dougados M, Berdah L, Amor B. Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum 1994;37:529-36.
50. Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Arthritis Rheum 2001;44:2539-47.
51. Fidelix TSA, Soares BGDO, Trevisani VFM. Diacerein for osteoarthritis. Cochrane Database Syst Rev 2006;1:CD005117.
52. NIH Consensus Development Panel on Total Hip Replacement. NIH consensus conference: total hip replacement. JAMA 1995;273:1950-6.
53. Fortin PR, Penrod JR, Clarke AE, et al. Timing of total joint replacement affects clinical outcomes among patients with osteoarthritis of the hip or knee. Arthritis Rheum 2002;46:3327-30.
54. Katz JN, Losina E, Barrett J, et al. Association between hospital and surgeon procedure volume and outcomes of total hip replacement in the United States Medicare population. J Bone Joint Surg Am 2001;83-A:1622-9.
55. Kirwan JR, Currey HL, Freeman MA, Snow S, Young PJ. Overall long-term impact of total hip and knee joint replacement surgery on patients with osteoarthritis and rheumatoid arthritis. Br J Rheumatol 1994;33:357-60.
56. Cutts S, Carter PB. Hip resurfacing: a technology reborn. Postgrad Med J 2006;82:802-5.
57. Murphy S, Deshmukh R. Periacetabular osteotomy; preoperative radiographic predictors of outcome. Clin Orthop Relat Res 2002;405:168-74.